PURPOSE: Persistent Staphylococcus aureus bacteremia (SAB) has been observed in patients with eradicated foci, but there are few studies of the risk factors and clinical outcomes of persistent bacteremia. This study determined the risk factors for persistent methicillin-resistant S. aureus (MRSA) bacteremia in patients without retained eradicable foci, including genotypic characteristics. METHODS: All adult SAB patients were investigated between 2008 and 2010. Persistent bacteremia was defined as bacteremia lasting >7 days after treatment and patients were monitored prospectively. The study included patients without retained eradicable foci, e.g., removed prosthetic devices and intravenous catheters removed after diagnosis, and those without metastatic infections. RESULTS: Persistent bacteremia occurred in 36 % (31/87) SAB patients with eradicated foci. There were no significant differences in successful defervescence (2.0 vs. 2.0 days, P = 0.55) and total length of hospital stay after bacteremia in the persistent bacteremia group and resolved bacteremia group (P = 0.32). The difference in MRSA bacteremia-related 30-day mortality with persistent bacteremia and resolved bacteremia was not significant (P = 0.12). However, agr dysfunction was higher in persistent bacteremia patients (94 %) than those with resolved bacteremia (75 %, P = 0.03). Multivariate analysis using a logistic regression model found that only agr dysfunction [odds ratio (OR) 4.83, 95 % confidence interval (CI) 1.02-22.89, P = 0.04] was an independent risk factor for persistent bacteremia. CONCLUSIONS: This study suggests that persistent bacteremia with eradicated foci might not adversely affect the outcome for MRSA bacteremia patients. agr dysfunction in S. aureus was significantly associated with persistent bacteremia.
PURPOSE: Persistent Staphylococcus aureus bacteremia (SAB) has been observed in patients with eradicated foci, but there are few studies of the risk factors and clinical outcomes of persistent bacteremia. This study determined the risk factors for persistent methicillin-resistant S. aureus (MRSA) bacteremia in patients without retained eradicable foci, including genotypic characteristics. METHODS: All adult SAB patients were investigated between 2008 and 2010. Persistent bacteremia was defined as bacteremia lasting >7 days after treatment and patients were monitored prospectively. The study included patients without retained eradicable foci, e.g., removed prosthetic devices and intravenous catheters removed after diagnosis, and those without metastatic infections. RESULTS: Persistent bacteremia occurred in 36 % (31/87) SAB patients with eradicated foci. There were no significant differences in successful defervescence (2.0 vs. 2.0 days, P = 0.55) and total length of hospital stay after bacteremia in the persistent bacteremia group and resolved bacteremia group (P = 0.32). The difference in MRSA bacteremia-related 30-day mortality with persistent bacteremia and resolved bacteremia was not significant (P = 0.12). However, agr dysfunction was higher in persistent bacteremiapatients (94 %) than those with resolved bacteremia (75 %, P = 0.03). Multivariate analysis using a logistic regression model found that only agr dysfunction [odds ratio (OR) 4.83, 95 % confidence interval (CI) 1.02-22.89, P = 0.04] was an independent risk factor for persistent bacteremia. CONCLUSIONS: This study suggests that persistent bacteremia with eradicated foci might not adversely affect the outcome for MRSA bacteremiapatients. agr dysfunction in S. aureus was significantly associated with persistent bacteremia.
Authors: Binh An Diep; Heather A Carleton; Richard F Chang; George F Sensabaugh; Francoise Perdreau-Remington Journal: J Infect Dis Date: 2006-04-21 Impact factor: 5.226
Authors: Kati Seidl; Arnold S Bayer; Vance G Fowler; James A McKinnell; Wessam Abdel Hady; George Sakoulas; Michael R Yeaman; Yan Q Xiong Journal: Antimicrob Agents Chemother Date: 2010-11-22 Impact factor: 5.191
Authors: Marin L Schweizer; Jon P Furuno; George Sakoulas; J Kristie Johnson; Anthony D Harris; Michelle D Shardell; Jessina C McGregor; Kerri A Thom; Eli N Perencevich Journal: Antimicrob Agents Chemother Date: 2010-12-20 Impact factor: 5.191
Authors: T Kim; E S Kim; S Y Park; H Sung; M-N Kim; S-H Kim; S-O Lee; S-H Choi; J-Y Jeong; J H Woo; Y P Chong; Y S Kim Journal: Eur J Clin Microbiol Infect Dis Date: 2017-03-23 Impact factor: 3.267
Authors: Fabienne Antunes Ferreira; Raquel Rodrigues Souza; Bruno de Sousa Moraes; Ana Maria de Amorim Ferreira; Marco Antônio Américo; Sérgio Eduardo Longo Fracalanzza; José Nelson Dos Santos Silva Couceiro; Agnes Marie Sá Figueiredo Journal: BMC Microbiol Date: 2013-04-27 Impact factor: 3.605
Authors: R L Richards; R D Haigh; B Pascoe; S K Sheppard; F Price; D Jenkins; K Rajakumar; J A Morrissey Journal: Infect Immun Date: 2015-06-08 Impact factor: 3.441
Authors: Gavin K Paterson; Ewan M Harrison; Gemma G R Murray; John J Welch; James H Warland; Matthew T G Holden; Fiona J E Morgan; Xiaoliang Ba; Gerrit Koop; Simon R Harris; Duncan J Maskell; Sharon J Peacock; Michael E Herrtage; Julian Parkhill; Mark A Holmes Journal: Nat Commun Date: 2015-03-27 Impact factor: 14.919
Authors: Deena R Altman; Mitchell J Sullivan; Bo Shopsin; Harm van Bakel; Kieran I Chacko; Divya Balasubramanian; Theodore R Pak; William E Sause; Krishan Kumar; Robert Sebra; Gintaras Deikus; Oliver Attie; Hannah Rose; Martha Lewis; Yi Fulmer; Ali Bashir; Andrew Kasarskis; Eric E Schadt; Anthony R Richardson; Victor J Torres Journal: Infect Immun Date: 2018-09-21 Impact factor: 3.441